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The human body seeks to maintain a stable physiological blood glucose 
concentration, despite a constantly changing availability of energy from eating. During 
food consumption, blood sugar would typically increase with time and during fasting, the 
opposite would be true. The body is able to release specific hormones to bring about 
either the storage or release of glucose from specific sites in the body. While this is all 
well and good, the body needs a sensor of sorts to determine when these actions need to 
take place. The brain, being the complex control center of the body, has such a site. The 
ventromedial hypothalamus is responsible for determining systemic glycemic levels. The 
exact mechanism that exists for the sensing isn’t fully understood, but it involves the 
VMH neurons. The loss of glucose, possibly due to fasting and a depleted amount of 
stored glucose, would lead to a response in the neurons that now lack fuel. While in a 
state of hypoglycemia, the neurons still need to function, and that is where the proposed 
astrocyte to neuron lactate shuttle hypothesis comes into play. 
This hypothesis suggests that glycogen stores in the astrocytes would be mobilized 
and converted to lactate, where it would be exported into the interstitial space and taken up 
via MCT2 proteins into the neurons to provide energy. In my study, we hypothesized that 
the knockdown of MCT2 proteins in the VMH will lead to an increased epinephrine 
response with recurrent bouts of exogenous-insulin induced hypoglycemia. Our results 
showed that MCT2 protein is very important to the function of energy sensing in the VMH 
and the loss of available lactate might simulate a bout of hypoglycemia
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CHAPTER I 
REVIEW OF LITERATURE 
 
 
Hypoglycemia 
The brain is a vital organ that regulates physiological change in the body. 
Changes in temperature, pH and blood sugar are just a few variables that are monitored 
and adjusted by the central nervous system. The ventromedial hypothalamus (VMH) is a 
primary brain area for controlling energy balance as well as the levels of circulating 
glucose through its influence on plasma catecholamines, insulin, and glucagon. These 
hormones are the major players in the normal control of blood glycemic levels. During 
hypoglycemia, the VMH senses a drop-in blood glucose below the normal functioning 
range. A variety of systemic changes return the body to a euglycemic state by activating 
redundant physiological systems. Two that I will highlight include the adrenomedullary 
response and the glucocorticoid responses. During a bout of hypoglycemia, the 
sympathoadreanal system releases norepinephrine(NE) and epinephrine(Epi) into the 
blood from the adrenal medulla, located near the kidneys. The VMH contains a variety of 
cell types. Two of interest are the glucose excitatory neurons (GE) and the glucose 
inhibitory neurons (GI). GE neurons increase activity during hyperglycemia. It has been 
suggested that GE neurons sense glucose in a manner similar to pancreatic beta cells: 
KATP channel that plays an important role in glucose sensing and blood sugar 
maintenance (28).  Rats with these KATP channels (Kir6.2) were blocked in the VMN lost 
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some of their glucose sensitivity (43). Conversely, GI neurons increase their rate of 
activity with a drop in ambient glucose levels. Murphy et al. 2009 collected brain slices 
to better understand the pathway by which the VMH GI neurons recognize 
hypoglycemia. They hypothesized that AMP activated protein kinase(AMPK) 
phosphorylates eNOS to increase nitric oxide production in VMH GI neurons due to a 
drop-in blood glucose (39). Maintaining sensitivity of GI neurons is important to 
preventing large downward swings in blood glucose. The loss of functionality by these 
cells in the VMH could lead to loss of hypoglycemic awareness.  
  
 
 
Figure 1. Cognitive and Metabolic Brain. The complex system of checks and balances to 
maintain euglycemia is accomplished through multiple endocrine signals. (14) 
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Initial glucose sensing studies revealed a role of brain sensing areas for blood sugar 
control. Damage to the fourth of a dog brain resulted in the onset of diabetes, leading 
scientists to believe that the brain played an important role in the body’s metabolic 
systems (3).  The hypothalamus came to light as a brain area where major metabolic 
shifts occur when this brain area is manipulated. For example, destruction of the VMH 
brings about hyperphagia and obesity (6). The VMH is one area in the brain that contains 
both glucose excitatory cells and glucose inhibitory cells (62). The brain consumes far 
more glucose then any organ in the body. Thus, a proper glucose level is required to 
maintain brain function.  
The hypothalamus contains glucose inhibitory neurons, which could help to sense 
and ultimately maintain proper glucose levels for the central nervous system (31). They 
also have been suggested to participate in the portioning of glucose throughout the 
endocrine system (27). During bouts of hyperglycemia, brain glucose levels were 
monitored and found to remain at a lower level despite 20mM systemic glycemic levels 
(52). Higher levels of glucose have been shown to hinder glucose sensing (9). Further 
work has been done to show that glucose in the VMH is similar to that of the arcuate 
nucleus, another portion of the brain which in encompassed in the hypothalamus. The 
arcuate nucleus, a portion of the VMH, does not contain GI or GE neurons. The VMH 
has been historically considered the satiety center of the brain, with the lateral 
hypothalamus being the feeding center. The administration of glucose in vivo into these 
two hypothalamic areas had a notably different effect, with glucose given to the VMH 
increased neuronal activity, and decreased when injected into the lateral hypothalamus 
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(42) Currently there are two types of established glucose sensing neurons: glucose-
excited (GE) and glucose-inhibited (GI) (55). The VMH contains GE neurons that are 
similar in function to the insulin secreting beta cells of the pancreas (2). A variety of 
hormones also influence the activity of glucose sensing neurons, with both insulin and 
ghrelin inhibiting GE neurons (58). Hypoglycemia did not have the repressing effect on 
GE neurons when insulin was administered (12). Hypoglycemia is readily detectable in 
the VMH, based upon the high levels of sensitivity by GE and GI neurons to a drop in 
physiological glucose (55).  
The counter regulatory physiological response (CRR) to hypoglycemia has three 
distinct components. A decrease in circulating insulin, an increase in glucagon, and the 
adrenomedullary release of epinephrine; the latter promote hepatic glycogen breakdown 
needed to maintain euglycemic and maintain glucose availability to the brain (13). VMH 
GI neurons have been shown to play a role in the CRR (56). A slight drop in blood 
glucose levels in a typically healthy individual is not a major concern and will not elicited 
these responses, as the body can quickly replenish circulating blood glucose 
concentration; however, insulin treatments may cause blood glucose to rapidly drop to 
levels that could cause permeant irreversible damage to portions of the brain which won’t 
properly function when deprived of glucose for even a short period of time. Chronic 
states of hypoglycemia can lead to coma and death. In advanced societies use of 
exogenous insulin is the leading cause of hypoglycemia.  
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Fuel Use in the Brain 
The brain requires a consistent supply of glucose to maintain its function. 
Activation within a brain area causes increased blood flow, and thus increased available 
glucose for energy production to support increased activity (30). During activation, 
glycolytic and oxidative metabolism was demonstrated to increase in synaptosomes in 
vitro (29). The use of glucose transporter (GLUT) proteins allows the brain to uptake 
available glucose from the blood (53). During prolonged hypoglycemia, the body enters a 
ketogenic state driven by a breakdown of long-chain fatty acids for oxidation into ketone 
bodies (35). the increase in fatty acid oxidation is supported by an increased ratio of 
glucagon to insulin. This could be due to loss of insulin production, the main 
physiological issue with diabetes mellitus type 1 (35). Ketone body production is not 
strictly due to an increase in FA availability, but rather the need for energy (35). The 
production of ketone bodies as an outlet for fuel production and utilization is important as 
it allows the body to spare what glucose is left for euglycemic maintenance. Acetone, B-
hydroxybutyrate and acetoacetate are produced in the liver. Ketone bodies are converted 
to actyl-CoA, where they can be utilized as substrate in the TCA cycle.  
The consumption of fuels by the brain has been termed flow dependent. Imaging 
studies documented changes in cerebral oxygen consumption, blood flow and glucose 
utilization are altered with brain activation (25). Increased blood flow paralleled glucose 
availability and oxygenation, but oxygen consumption in not as greatly increased 
compared to the uptake of glucose and increased regional cerebral blood flow (30).  A 
variety of studies have discussed possible sources of energy during this activation. Early 
6 
 
work with H1 NMR in vivo showed that physiological lactate increases in the visual 
cortex with photic stimulation (48). It could be assumed that brain activation causes an 
increase in lactate to provide additional energy to neurons. Later, it was suggested that 
lactate was released from astrocytic cells via the signaling functions of glutamate (24). 
This sets the basis for the astrocyte to neuron lactate shuttle (ANLS) hypothesis 
(described in more detail below). Monocarboxylic transporters (MCTs) are proteins that 
transport lactate across membranes. Monocarboxylic transporter 2 (MCT2, primarily 
expressed in the neurons, is a proton driven membrane protein which is affected little by 
electrical membrane potential (8).  MCT2 is considered to have a much higher affinity for 
lactate and pyruvate compared to MCTs 1 and 4, which are associated with glia (7). 
There may be a transient increase in lactate uptake by activated neurons, although 
astrocytes may also be involved in uptake and utilization of free lactate (54). The infusion 
of lactate into the VMH was shown to inhibit the CRR in vivo, (5) while the 
administration of lactate in vivo blunts VMH GI neurons during a drop-in glucose levels 
(56).  
 
Recurrent Hypoglycemia 
While the brain has multiple levels of protection to prevent large and prolonged 
changes from euglycemic, hypoglycemia can still become a problem. Incidents of 
hypoglycemia are noted in overall healthy individuals who exercise without proper 
glycogen stores, such as one who undergoes intensive training in the morning after an 
over-night fast (24). Individuals who suffer from diabetes mellitus type I are prescribed 
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exogenous insulin injections to lower blood glucose. This is a great treatment for 
correcting hyperglycemia, but improper dosages or lack of physiological correction for 
the excess insulin can lead to hypoglycemia. Diabetes mellitus type II patients are 
typically advised to make life style modifications to better their overall health, but drugs 
and insulin therapy are becoming a mainstream way of controlling blood sugar levels. In 
fact, twice as many diabetic individuals suffer from hypoglycemia each year when taking 
insulin compared to those who primarily practice good lifestyle choices (16).  
 
 
Figure 2. Integration of Brain Function. Antecedent hypoglycemia leads to recurrent 
hypoglycemia bouts via defective glucose counterregulation and philological 
hypoglycemia unawareness. (14) 
 
 In type I diabetic individuals, the loss of glucagon production with the 
progression of the disease make the release glucose via glycogenolysis and glycogenesis 
mediated by epinephrine even more important. These individuals may have a 
compromised response to hypoglycemia. Hypoglycemia could become a major issue 
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when combined with fasting and/or inaccurate insulin injection. Individuals who 
‘overdose’ themselves with insulin, possibly due to either miscalculations on the 
administered amount, are at risk of prolonged severe hypoglycemia. Recurrent bouts of 
hypoglycemia have been shown to decrease the scope of the counterregulatory responses 
to restore normal glucose concentrations. Repeated hypoglycemia can numb the 
individual to being aware of their hypoglycemic status and lead to a diminished 
autonomic response, coined hypoglycemic associated autonomic failure (HAAF). HAAF 
decreases the typical physiological responses that are clinical markers of hypoglycemia. 
This includes fatigue, anxiety, heart palpitations and a ‘cloudy head.’ This hypoglycemic 
unawareness presents a positive feedback loop that develops with repeated hypoglycemic 
episodes.  
  
Brain Glycogen 
The utilization of brain bound glycogen by the neurons is receiving increased 
attention. As previously stated, during activation, the brain consumes glucose at a higher 
rate. This is possibly augmented by stores of glycogen in the astrocytes. The storage of 
glycogen in the brain was originally thought to be primary to provide glucose and energy 
allotment during situations where available glucose was limited. The glycogen could act 
as a short-term pool of glucose to allow continued function (51). Later literature showed 
that this glycogen was consumed at such a rate as to be inefficient for function over long 
periods of time (32). Later studies conducted by Swanson et al. determined that glycogen 
was consumed during whisker stimulation in the barrel cortex region of the brain (61). 
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Thus, glycogen was utilized in specific scenarios, but how it was being used was still 
unknown. A variety of pathways are applicable for glycogen. A proposed pathway by 
Dringen et al. points to the generate lactate which is then exported from the astrocytes 
into the blood or neuronal cells to provide a source for ATP generation (18).  
The synthesis and breakdown of glycogen is heavily controlled. Glycogen in the 
brain is concentrated in the astrocytes, as is glycogen phosphorylase needed to utilized 
the stores (40). Although studies show insignificant glycogen stores for brain function 
during oxygen starvation, DiNuzzo et al.  proposed that astrocytic glycogen could be 
useful for situations of brain activation (17). Knockout of glycogen synthase reduced 
learning abilities, and available glycogen plays a hardy role when brain areas are 
stimulated (20). Though this work was done in the hippocampus, it could be a similar 
response to glucose sensing activities in the hypothalamus.  
A single bout of severe hypoglycemia leads to increased glycogen storage (19). 
This was evident regardless of blood glucose levels during recovery, and 
supercompensation was shown in the hippocampus, cortex and striatum, but was absent 
in the hypothalamus (19). Episodes of hypoglycemia have been touted as leading to an 
increased expression of glucose carriers (53). This would theoretically lead to increased 
glycogen stores with greater transport faculties. Increased glycogen concentration was 
studied as a possible link to hypoglycemia unawareness.   Supercompensation of brain 
glycogen was studied by Canada et al. 2011 where brain glycogen amounts were 
determined in mice after bouts of acute or recurrent hypoglycemia (10). Their findings 
suggest that glycogen stores increase after hypoglycemia, and that the change in glycogen 
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degradation and reaccumulation occur to the same extent in instances of acute or 
recurrent hypoglycemia (9). 
 
Astrocyte to Neuron Lactate Shuttle 
Glutamate is a major signaling neurotransmitter in the brain involved with the 
activation of neurons. Pellerin and Magistretti 1994. surmised that glutamate ultimately 
leads to glycolysis in the astrocytes to provide energy, via glycogen stores, to the neurons 
when increased energy is needed. Neuron function in brain slices was restored with the 
administration of L-lactate (60). The ANLS hypothesis is supported by the idea that all 
neurons contain Lactate dehydrogenase 1 (LDH1) and Lactate dehydrogenase-5 (LDH5) 
proteins which allow the inter-conversion of lactate and pyruvate.  
 The hypothesized astrocyte to neuron lactate shuttle (ANLS) suggests that the 
neuron in the brain receives lactate via the astrocyte through monocarboxylic transport 
proteins (MCTs) (46). The movement of lactate out of the astrocyte via MCT1 and 
MCT4 proteins allows lactate to move into the intracellular space to be taken up by 
neurons through MCT2 membrane proteins. This has been the driving idea, with MCT4 
being primarily expressed on the astrocyte, and MCT2 primarily found on the neuron 
(47). Lactate can then be converted to pyruvate through the Cori cycle for ATP 
generation. It has also been hypothesized that the generation of lactate from glycogen 
stores in the astrocytes works to spare remaining glucose for neurons (17). Suzuki et al 
reviewed past experiments which sought to determine the role of lactate and proposed the 
lactate to neuron shuttle facilitates long-term memory formation in rat hippocampus (59).  
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These authors hypothesized that increases in lactate during memory formation, 
specifically long term, provide extra fuel for neurons in the hippocampus. They used 
Oligodeoxynucleotides (ODN) to knockdown specific MCT protein in the hippocampus. 
During memory formation, rats given MCT4 and MCT2 ODNs exhibited notable lack of 
memory formation, possibly due to the lack of lactate shuttling. Memory formation was 
ultimately restored in groups given the MCT4 and MCT1 ODNs through the 
administration of exogenous lactate. This was not the case for MCT2 ODN groups, where 
the administration of lactate did not restore cognitive faculties.  
 
 
Figure 3. Astrocyte to Neuron Lactate Shuttle. MCT1 and MCT4 move lactate out of the 
astrocyte, while MCT2 moves interstitial lactate into the neurons.  
 
Oberlin et al (unpublished studies) measured the effect of recurrent verses acute 
hypoglycemia on MCT protein expression in various tissues. The study found no increase 
in MCT in the hypothalamus. MCTs were also not shown to change with bouts of 
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exercise induced HAFF. MCTs may not be important to maintaining glucose through 
sensing neurons, but their role in lactate transport still carries itself as its primary role 
(40). 
 
Availability of Lactate and Study Design 
Our study seeks to investigate the mechanisms behind glucose sensing, counter 
regulation and brain function during hypoglycemia. The proposed increase in brain 
glycogen after a single bout of hypoglycemia could lead to increased levels of available 
lactate to the neurons. The increased levels of glycogen in the astrocytes would provide 
alternative available substrate to provide energy for the neurons, despite a decrease in 
glucose levels. The VMH was the brain area targeted, and the adrenal response analyzed 
and interpreted. This study focuses in on the effects of MCT2 knockdown, and the sub 
sequential theoretical decrease in available lactate, and the change in epinephrine released 
due to hypoglycemia. 
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CHAPTER II 
METHODS 
 
Male Sprague-Dawley rats (Charles River, Raleigh, NC) weighing approximately 
200g were single housed in a light (12 hour on off cycle) and temperature (25+/- 2 C) 
controlled vivarium and given unlimited access to food (18% protein global chow, Harlan 
Teklad Labs, Dublin VA) and water. All animal studies were approved by the University 
of North Carolina at Greensboro’s Institutional Animal Care and Use Committee 
(IACUC).  
 
Animal Surgery 
Rats were administered Xylazine at 10mg/kg before being placed in anesthesia 
chamber and administered vaporized isoflourene at 3.2% until sedated. Rat were the 
removed and a nosecone placed to anesthesia via a Kent Scientific Sumnosuite low-flow 
anesthesia delivery system (2014, Kent Scientific Corporation, Torrington CT). 
Isoflurane flow rate was reduced to 1.6% and held there until the completion of the 
surgery. The rats were prepared by shaving the crown of the head and the area of the neck 
where the jugular vein was located, while keeping the eyes properly lubricated to prevent 
drying and damage. The areas were cleaned with a combination of ethanol and iodine to 
prevent infection. Carprofen was administered at 5mg/kg into the hindquarters, and a 
bolus of 0.25% bupivacaine was injected under the skin of the scalp to decrease post-
surgical pain. 
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The surgical field was isolated using cling wrap and an incision was made on top 
of the skull with the scalpel. The rat was then flipped over and a similar incision was 
made in the neck. The jugular vein was identified and a silastic catheter was inserted into 
the vein. The other end of the catheter was then run along the neck under the skin and 
extracted from the incision site on the top of the head. The rat was then moved to the 
stereotaxic and held in place via two ear canal anchors to prevent misalignment. The 
skull was scraped with the scalpel to debride the surface and prevent bleeding. Gelfoam 
was used liberally to curb bleeding. Three holes were drilled in the skull of the subject 
with an electric surgical drill and fitted with 1.25mm screws to act as anchors. Two 
smaller holes were drilled 0.8mm to the right and left of centerline. Another 2.4mm to the 
posterior of bregma was then marked and cannula guides were inserted 6.0mm into the 
brain to position them 2mm above the VMN. Once placed, dental acrylic cement was 
applied to the skull and allowed to solidify. The cannulas and the port for the catheter 
were filled with a stylet to prevent coagulation and infection. The catheter was filled with 
heparin glycerol solution to prevent coagulation in the tubing.  After the surgery, 
Carprofen was administered at 5mg/kg/d to reduce pain and anxiety.  
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Day 1 Day 2 Day 3 Day 4 
Scrambled 
Acute 
Scrambled ODN Saline Saline Insulin 
Scrambled 
Recurrent 
Scrambled ODN Insulin Insulin Insulin 
Anti-MCT2 
Acute 
MCT2 ODN Saline Saline Insulin 
Anti-MCT2 
Recurrent 
MCT2 ODN Insulin Insulin Insulin 
 
Figure 4. Experimental Design. This protocol schedules the ODN injections and recurrent 
hypoglycemic events in our rat models. Days 1 involved VMH injection while days 2-4 
are either saline or insulin injections. 
 
ODN Injections 
 
All animals were given two days to recover after the surgery before the ODN 
injections. On the third day, rats were no longer dosed with carprofen. The Harvard 
PicoPlus perfusion pump was utilized, and injection cannula were fitted with a prefilled 
PE tubing containing either MCT2 antisense (5’-GACTCTGATGGCATTTCTGAG-3’) 
or scrambled control (5’-GGTTTACGAGTCGTCCGTAAT-3’) , and delivered at 0.1uL 
per min over 10mins. The rats were allowed to roam freely during administration of the 
ODNs, while taking care to prevent dislocation of injection needles.  once complete, 
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injection needles were left in place for 5 minutes before being slowly removed and the 
stylets reinserted.   
 
Blood Sampling and Tissue Extraction 
 
Blood samples were collected over three consecutive days, with the first day 
starting the day after ODN injections (day 2). Food dishes for the rats were removed each 
morning before blood sampling. To minimize stress, blood samples were collected from 
an animal’s home cage via tubing connected to the jugular vein access port. Two baseline 
samples were collected at -10 and 0 minutes before the administration of either insulin (3 
units/kg) or saline. On days 2 and 3, additional blood sample was collected 30 and 60 
minutes after insulin or saline. On day 4 all animals received insulin and blood was 
collected 15, 30, 60, 90, and 120 minutes after insulin. Approximately 250 microliters of 
whole blood were collected at each time point. Each sample was briefly centrifuged for 
10-15 seconds at 6000 rpm and 100 microliters of plasma were harvested. Blood volume 
was maintained by resuspending harvested red blood cells in a volume of 0.9% sterile 
saline solution equal to the amount of plasma removed at each time point. The 
resuspended red blood cells were readministered to each animal through the jugular vein 
at the time of sampling.  plasma was stored at -80oC for later analysis.  
Rats were euthanized in a CO2 chamber; the brain was taken out and a 2mm slice 
containing the VMH isolated. Punches were taken from the ventromedial nucleus with 
18gauge blunted needle. The remainder of the ventromedial hypothalamus was taken and 
stored in a separate tube. Both were stored at -80oC until thawed for analysis.  
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HPLC for Catecholamine Analysis 
 
High performance liquid chromatography was used to determine plasma 
concentrations of norepinephrine and epinephrine using a ESA Coulochem II detector 
and Thermo Scientific UltiMate 3000 system (Fisher Scientific). All samples were 
thawed on ice while initial preparation in Eppendorf filter tubes. 10μg of aluminum oxide 
were added to each tube. Tris buffer was added at 500μL per tube, followed by 80μL of 
DHBA standard at 1pg/μL concentration. Finally, 100μL of plasma was added to each 
tube, after being lightly vortexed. Tubes were then agitated for 10min at room 
temperature. All tubes were centrifuged at 12000rpms for 3mins at 4oC, or until all of the 
tris buffer had cleared the filter. From there, each sample was washed with 500μL of 
water for 1min in the centrifuged at 12000rpm, or until the water completely cleared the 
filter. This was repeated a total of four times. The filter was then transferred to another 
150μL sample tube, and 80μL of 0.2N perchloric acid was placed in each filter. Samples 
were vortexed briefly (1-2min) and allowed to incubate at room temperature for 5min. 
Tubes were centrifuged at 12000rpm for 2 minutes, or until the acid had completely 
cleared the filter. Samples were then placed in HPLC sampling tubes and analyzed. All 
samples were run at 0.275mL/min with column pressure between 2000psi and 2200psi.  
 
Western Blotting 
Brain punch samples were removed from -80oC freezer and homogenized in 
150μL of a 10:1 solution comprised of RIPA buffer and phosphatase inhibitor. Specific 
protease inhibitors were added at 100:1 ratio of total volume. Samples were sonicated on 
ice using a Fisher Scientific Sonic Dismembrator Model 50 at the lowest setting. Three 
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hits of the sonicator were used for each tube. Tubes were then centrifuged for 15min at 
14000rpms at 4oC. All sample were aliquoted out at 20μL per tube edit one frozen at -
80oC until ready to use. Total protein was assessed using a Pierce BCA kit and a BioTek 
Epoch plate reader.  
On day one of western blotting, homogenized VMN brain samples were thawed 
on ice. Western blots were performed to determine the presence and amount of MCT2 
protein. Plates and holders were cleaned with 70% ethanol and allowed to dry. Plates 
were inserted into holders, using spacers to allow for internal area. The plate was set on a 
Hoffman electrophoresis stand, and anchored in placed via attachment screws. Plates 
were marked as a reference to where the stand would be filled with resolving gel. The 
12% resolving gel (see formula appendix) was made and placed in between the plates 
3mL of DI water was pipetted on top to prevent drying. The gel was allowed to sit for 
30min to completely set up, while being watched for leaks. After 30min, the water was 
poured off, and a stacking gel was made and pipetted on top of the resolving gel. The 
bottom of the stand was filled with electrophoresis buffer, prepared fresh for each run. A 
fifteen well fork was cleaned with 70% ethanol and placed in the stacking gel while it set 
up over the next 30min. Once the stacking gel was established, VMH homogenate was 
combined with an equal part of loading buffer (see formula appendix) and was lightly 
vortexed and pipetted into each lane at 50μg per lane with volume determined from the 
Pierce BCA. If the total volume to make 50μg was too large for the well, a lesser volume 
was pipetted and the volume was recorded. Samples were kept on ice throughout process. 
A lane marker (MagicMark) at 2μl was run alongside samples to act as a weight marker 
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for protein migration. The set up was filled with electrophoresis buffet and run over night 
(15-16hr) at 65mV. 
 
Figure 5. Western Blotting Setup. This shows the device breakdown for the running of 
gel transfer electrophoresis, giving appropriate positioning of the pads and filters needed 
to establish protein bands on PVDF membrane. (Image via Bolster Bio, Pleasanton CA) 
On the second day, the protein bands were transferred to a PVDF membrane. The 
membrane was soaked in methanol and sandwiched between 2 sponges and 2 pieces of 
filter paper while being pressed against the gel. The plate was then placed in a transfer 
cassette for 6hr at 200mA. The cassette was buried in ice to prevent excess heat 
generation. After the transfer was completed, The PVDF membrane was washed in TBST 
for 5min on a Bigger Bill orbital shaker at 100rpm. The TBST was then discarded and a 
solution of 5% Saco mix and drink powdered milk and TBST was used to wash the 
membrane for 1hr at 100rpm. The membrane was then washed in TBST three times for 
5min, while boxes for primary antibody were washed for 15min in 5% milk. The 
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membrane was then placed in the box with 15mL of 5% milk and primary antibody for 
MCT2 (Santa Cruz sc-50232) at a 1:250 ratio. The primary antibody was allowed to 
block overnight (15-16hr) on a Speci-Mix rocker at 4oC.  
 
Figure 6. Western Blot for MCT1 Protein. Dark bands in the middle represent the protein, 
the right most well is the Magicmark ladder for determining weight of proteins.  
The following day, the milk was discarded and the membrane was washed in 
TBST for 10min. The membrane was then washed again with TBST and 5% milk three 
times for 30min, discarding and replacing milk every 10min. During this phase, boxes for 
secondary antibody binding were blocked for 30min in 5% milk. The milk was discarded, 
and the secondary anti-rabbit (Pierce 31460) was applied in 15mL of milk at 1:5000 for 2 
hours at room temperature. The milk was discarded, and the membrane was washed in 
TBST four times for 10min each, discarding after each wash. ECL plus was used to soak 
the membrane before exposure. The membrane was exposed on a BioRad Chemidoc 
Station eight times over 300s. The band densities were determined using the densitometry 
tool in the QuanitiyOne software. Once the exposure had finished, the membrane was 
washed two times for 10min per wash in stripping buffer. Once the stripping was 
complete, the membrane was washed for 10min four times in TBST. The membrane was 
then blocked in 5% milk for 1hr on the orbital shaker. The milk was discarded after an 
hour, and the membrane was washed three times for 5min per wash in TBST. 
Concurrently, the box for administration of secondary antibody was washed in 5% milk 
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for 15min. The membrane was placed in the box with 15mL of 5% milk and primary 
antibody for GAPDH (Santa Crux sc-166545) at a ratio of 1:4000, and left on a rocker 
overnight at 4oC.  
 
Figure 7. Western Blot for GAPDH Control. This gives the ratio of MCT proteins to 
unaffected control to determine if the amount of protein was affected during ODN 
treatment. 
After the overnight probe with GAPDH, the milk was discarded and the 
membrane was again washed in TBST. The membrane was then washed three times in 
5% milk for 10min per wash. While this was occurring, the box for secondary antibody 
was washed for 30min with 5% milk. The membrane was then place in this box with 
15mL of 5% milk and secondary anti-mouse (Pierce 31450) at 1:2000 for 2hr at room 
temperature. Once the secondary anti-body had finished, the membrane was washed four 
times for 10min each in TBST. The membrane was again soaked in ECL solution and 
exposed eight times for 300s on the Chemidoc Station. Densities were determined using 
the densitometry tool on the QuantityOne software. Densities of MCT2 and GAPDH 
were compared to determine the ratio between two proteins, and relative MCT2 
expression in the VMN.  
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Statistical Analysis 
Data analysis and graphing was completed using Prism (GraphPad Software, Inc., 
La Jolla, CA). I performed a two-way repeated measures ANOVA to compare plasma 
epinephrine to blood glucose levels. The was also used to analyze the changes in plasma 
epinephrine and blood glucose over the experimental time periods for group statistical 
significance. A one-way ANOVA was used for the majority of data collected. I used this 
test for MCT2/GAPDH ratio and compare vs experimental groups. A post-hoc T-test of 
variance was used when significance was determined. A linear correlation was 
implemented to set MCT2/GAPDH ratio verses baseline and peak plasma epinephrine 
levels. 
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CHAPTER III 
RESULTS 
 
MCT2 protein expression in the VMH (Figure 8) of rats administered the MCT2 
antisense ODN was reduced to ~57% of non-injected and scrambled ODN- administered 
animals (F2, 35 = 33.93, P<0.001). Values are presented as percent of non-injected. No 
statistical differences were seen between the control (scrambled ODN) and non-injected 
groups.  
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Figure 8. MCT2 Expression in the VMH. MCT2 protein in the ventromedial 
hypothalamus (VMH) 4 days following injection of scrambled (n=16) or anti-MCT2 
(n=14) oligodeoxynucleotide into the VMH. Values are as a percent of non-injected 
(n=6) rats. Bars with same superscripts are not different. 
 
Plasma glucose decreased (F3, 30 = 44.12, P<0.001) similarly across groups in 
response to the first 2 bouts of insulin-induced hypoglycemic episodes (days 2 and 3, 
Table 1). The increase in plasma epinephrine concentration following insulin was 
apparent only after the first episode of hypoglycemia in the scrambled ODN group (F3, 30 
= 5.08, P<0.001). 
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Table 1. Days 2 and 3 Blood Glucose and Plasma Epinephrine Levels. Plasma glucose 
(mg/dL) and epinephrine (credit pg/mL) 60 minutes after administration of saline (acute) 
or insulin (recurrent).  
 
 
 
 
 
 
 
 
 
 
 
 
Rats were administered oligodeoxynucleotide targeting MCT2 or a scrambled 
sequence into the ventromedial hypothalamus on day 1. Values with similar superscripts 
are not different, as determined by two-way ANOVA and tukey’s post hoc analysis.  
(Scrambled acute: n=6, Scrambled recurrent: n=6, anti-MCT2 acute: n=5, anti-MCT2 
recurrent: n=5). 
 
 
 
 
  day 2 day 3 
Glucose (mg/dL)    
Scrambled acute 115 ± 8 a 118 ± 12 a 
 recurrent 62 ± 7 b 50 ± 2 b 
Anti-MCT2 acute 121 ± 4 a 128 ± 4 a 
 recurrent 55 ± 10 b 59 ± 2 b 
    
Epinephrine (pg/mL)    
Scrambled acute 161 ± 29 a 114 ± 56 a 
 recurrent 953 ± 54 b 475 ± 90 a 
Anti-MCT2 acute 252 ± 6 a 278 ± 62 a 
 recurrent 410 ± 76 a 366 ± 95 a 
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Blood glucose (Figure 9) was reduced from baseline (F5, 90 = 44.46, P<0.001) to a similar 
degree in all groups following insulin administration on day 4.  
 
Figure 9. Change in Blood Glucose Over Time on Day 4. Blood glucose following 
insulin administration, at time= 0, on experimental day 4. means ± standard error.  all 
points were different (P< 0.05) from baseline (time= 0) but there were no differences 
between treatment group as determined by repeated measure two-way ANOVA.  (Sc Ac: 
Scrambled Acute: n=6, Scrambled recurrent: n=6, anti-MCT2 acute: n=5, anti-MCT2 
recurrent: n=5) 
 
The increase (F5, 90 = 6.82, P<0.001) in plasma epinephrine (Figure 10) following 
insulin administration on day 4 was limited to the rats receiving scrambled ODN.  
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As expected, the epinephrine response was attenuated in the recurrent group; total 
response, e.g. area under the curve, was 52% of acute group (F1,18 = 4.58, P<0.05). 
Significant changes were seen in the scrambled acute group at 15min and 60min 
compared to all other groups. The scrambled acute group was significant from both 
antisense groups and the scrambled recurrent group. at the 30min time point. The 
scrambled recurrent group was significantly different from the scrambled acute group and 
both of the antisense groups at the 30min time point. The scrambled acute and scrambled 
recurrent group showed statistical significance between each other and against both 
antisense groups. Significance was noted at the 90min time point between the scrambled 
and antisense groups, but not between scrambled and acute of the same group. No 
significant difference was noted between the antisense groups against each other at any 
time point. P=0.05 
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Figure 10. Change in Plasma Epinephrine Over Time on Day 4. Changes in plasma 
epinephrine following insulin administration, at time= 0, (top panel) and area under the 
curve (bottom panel) on experimental day 4. Values are means ± standard error. Top 
panel:   # Sc Ac different (P< 0.05) from all other groups, *Sc RH different from 
antisense group, &scrambled groups different from antisense groups as determined by 
repeated measure two-way ANOVA and Tukey’s post hoc analysis. Bottom panel: bars 
with similar superscripts are not different as determined by one-way ANOVA and 
Tukey’s post hoc analysis.   (Sc Ac: Scrambled Acute: n=6, Scrambled recurrent: n=6, 
anti-MCT2 acute: n=5, anti-MCT2 recurrent: n=5) 
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One cohort of rats receiving the antisense responded differently to insulin on day 4 
(Figure 4). Blood glucose recovered quickly in this group despite receiving the same dose 
of insulin and the absence of an increase in plasma epinephrine. Baseline concentrations 
of epinephrine were almost threefold higher (F3,20 = 12.74, P<0.001) and MCT2 
expression in the VMH (Figure 11) fourfold lower (F3,36 = 70.42, P<0.001) in these 
animals which we termed ‘nonresponders’. 
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Figure 11. Anti-sense Day 4 Blood Glucose and Baseline Epinephrine. top panel: change 
in blood glucose levels in antisense groups on day 4.  bottom panel: baseline epinephrine 
level on day 4 baseline, at time point zero. P =0.05 (Sc Ac: Scrambled Acute: n=6, 
Scrambled recurrent: n=6, anti-MCT2 acute: n=5, anti-MCT2 recurrent: n=5) 
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Figure 12. MCT2 Levels in Scrambled, Anti-sense and Non-respondents. MCT2 
expression in the VMN following injection of scrambled or anti- MCT2 ODN into the 
VMH. The level of expression in antisense and non-responders is compared to the 
scrambled group. All groups were analyzed via Chemidoc densitometry, and all groups 
show statistically significance from all other groups.  P=0.05 (scrambled: n = 12, 
antisense: n = 8, non-responders: n = 5) 
 
There was a negative correlation (r2 = 0.68; F1,16 = 34.34, P<0.001) between 
baseline epinephrine concentrations and MCT 2 expression in the VMH (Figure 13). 
There was also positive correlation (r2 = 0.20; F1,16 = 3. 96, P =0.06) between peak 
epinephrine response (on day 4) and MCT 2 expression. 
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Figure 13. MCT2/GAPDH Expression Correlation to Epinephrine Levels. Scatter plot 
comparing ratio of MCT2/GAPDH to baseline and peak plasma epinephrine response to 
hypoglycemia on day 4. Blue dots represent correlation between baseline plasma 
epinephrine levels and MCT2 expression ratios. Red dots indicate correlation between 
peak levels of epinepherine on day 4 and MCT2 expression ratios. P=0.05 (peak: n=18, 
baseline: n=18) 
 
There was a 54% decrease (F2,20 = 18.37, P<0.001) in MCT1 protein expression 
levels in the VMH only in the "non-responders" group (Figure 14). This decrease was not 
apparent in all rats receiving the anti-MCT2 ODN, as MCT1 protein expression was 
similar to rats receiving the scrambled ODN and non-injected animals. 
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Figure 14. MCT1 Expression Levels in the VMH. MCT1 protein expression levels in the 
VMH. The white bar represents scrambled rats, the red bar represents the antisense group 
and the blue bar represents the antisense nonreponders. A one-way ANOVA was 
completed to determine significance. P=0.05 (scrambled: n = 12, antisense: n = 8, non-
responders: n = 5) 
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CHAPTER IV 
 
DISCUSSION 
 
Normal lactate transport in neurons of the VMH is necessary for the 
sympathoadrenal response to hypoglycemia. The customary increase in plasma 
catecholamines during insulin-induced hypoglycemia was absent when MCT2 protein 
expression in the VMH was reduced by MCT2 antisense ODN. The influence of lactate 
availability to neurons in the VMH on CRR demonstrated that lactate is probably an 
important fuel source for the brain. This is not only during bouts of hypoglycemia, but for 
situations when energy is needed beyond the available glucose. In the VMH, neuronal 
lactate uptake influences GABAergic activity, which has been associated with the CRR. 
Chan and associates reported increase in GABA concentrations in the VMH to exogenous 
lactate was blocked by the MCT inhibitor α-cyano-4-hydroxy-cinnamate (4-CIN). 
Exogenous lactate in the VMH during hypoglycemia reduced the CRR (Borg and Chan 
papers) and inhibiting lactate transport with 4-CIN restored the blunted CRR during 
recurrent hypoglycemia (11). The authors suggested lactate serves as an alternative fuel, 
and perhaps a preferential fuel following antecedent hypoglycemia, to glucose sensing 
neurons. During recurrent hypoglycemia, the lack of available glucose could cause the 
increased utilization of lactate for neuronal fuel (21). Song and Routh (52) reported 
convincing evidence of an effect of lactate on glucose sensing neuron activity in the 
VMH. The same authors noted a similar decrease in glucose sensitivity of GI neurons  
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following recurrent hypoglycemia was induced by supplemental lactate (53). The 
complete absence of a plasma epinephrine response to hypoglycemia when MCT2 
expression was reduced in the VMH was surprising. Given the KM for lactate by MCT2 is 
~ 0.75uM and baseline interstitial lactate concentrations 1.5-2.0 uM in the VMH (11) we 
expect the 50% decrease in MCT2 protein expression resulted in a decrease in lactate 
transport into neurons. 4-CIN administered into the VMH restored plasma epinephrine 
response following recurrent hypoglycemia (11); however, these authors did not measure 
the CRR when 4-CIN was administered prior to acute hypoglycemia. One response to 4-
CIN, and disruption of lactate supply, may be an increase in glucose uptake by neurons 
(21) and it is possible the chronic decrease in lactate uptake induced by reduced MCT2 
expression was compensated by an increase in the capacity for glucose uptake. Fan and 
colleagues (22) used in shRNA approach to reduce expression of the glucose transporter 
SGLT1 in the VMH and noted an improved the CRR following recurrent hypoglycemia. 
The ~53% decrease in SGLT1 was similar in magnitude to the decrease in MCT2 
expression of the present study; however, unlike the present study the CRR to acute 
hypoglycemia was augmented instead of suppressed.  
It is unlikely the expected reduction in MCT2 activity in the VMH itself 
prevented an increase in plasma epinephrine. A cohort of animals with a more severe 
reduction (~80% below controls) exhibited baseline plasma epinephrine concentrations 
that were fivefold higher. It is unclear if the higher baseline epinephrine levels were a 
direct effect of the reduced MCT2 on neurons regulating sympathoadrenal response. 
Although we did not observe any unusual behavior this subgroup of animals may have 
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been more sensitive to stress, for example associated with handling at the time of blood 
sampling. The elevated baseline level of epinephrine may account for the rapid rebound 
in plasma glucose in these rats. The high levels of epinephrine could have jump started 
glycogenolysis and gluconeogenesis.  In addition, it is unlikely disruption in normal 
lactate transport resulted in general dysfunction in the VMH. Lesions to the VMH result 
in hyperphagia and obesity (4) and those rats receiving the antisense treatment 
maintained normal body weights and blood glucose levels. While the CRR to 
hypoglycemia was absent in rats with VMH lesions baseline epinephrine was not 
elevated in VMH-lesioned rats (4). In addition, western blotting of MCT1 revealed that 
the ODN for MCT2 did not have a deleterious effect on MCT1 expression.  
A blunted plasma epinephrine response would not be expected with the first day 
of hypoglycemia; however, this appeared to be the case in the antisense group. The 
increase in plasma epinephrine observed in the scrambled ODN group 60 minutes after 
the initial hypoglycemic episode was absent in both groups of rats receiving the antisense 
ODN. An interesting possibility is whether inhibition of MCT2 protein expression up to 
50% would imitate a state of hypoglycemia by reducing fuel availability to neurons, 
including glucose sensitive neurons, in the VMH. It may be the initial response, during 
the first 24 hours, after antisense administration was a disruption in fuel supply in the 
VMH analogous to what would occur during hypoglycemia. We did not evaluate for a 
counter regulatory response during this period. The decline in protein expression would 
be expected to limit to, a certain extent, the flow of lactate into the neurons and could 
initiate an adrenergic medullary response. If so, this would be expected to lead to a 
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blunted CRR to subsequent hypoglycemia. We are unaware of any reports for antecedent 
lactate deprivation and normal CRR to hypoglycemia.  
MCT proteins are located on both the astrocytes and the neurons in the VMH. 
MCT2 has been experimentally determined to be expressed in the neurons of whole 
brain. MCT4 has been shown to export lactate from the cell it is located on, and is found 
primarily on the astrocytes in rodent brains. MCT1 is prolific throughout the cells of a 
postnatal developing rat. The levels of expression decrease over time but are never found 
in the neurons in large quantity. our methods did not differentiate where MCT2 proteins 
were located in the VMH, whether or not the reduction in MCT2 proteins were in the 
neuronal versus mitochondrial membrane. Although expression of MCT2 protein has 
been shown to be primarily expressed in the neurons within the VMH, homogenization 
makes it impossible to determine the exact location of expression and function. 
Throughout our work and the work of Suzuki et al. the potency of the MCT2 ODN was 
shown at varying levels and the effects that they had on the ability to bring lactate into 
the neuron. The lack of learning present in the rats given the ODN, followed by the 
infusion of lactate to restore it provides solid evidence that MCT2 is providing lactate to 
the neurons to aid in learning. Whereas MCT1 and MCT4 knockdown rats could be 
rescued via the infusion of lactate, MCT2 knockdown rats had no change verses the rats 
not given lactate (60.) The Western blotting of MCT2 shows that it was decreased in both 
our study and Suzuki et al. Our blotting of MCT1 shows the specificity of the ODN, as 
no change in expression was noted, albeit from the non-respondent group, whose 
members showed different outcomes all together.  
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In the present study, reducing MCT2 expression in the VMH, using specific antisense 
ODN, suppressed the plasma epinephrine response to both an acute episode and recurrent 
episodes of hypoglycemia. There were no obvious behavioral or physiological indicators 
of impairment to this brain area by the treatment. These results support the importance of 
these transporters and the potential significance of changes in lactate availability on the 
physiological response to changes in glycemic status.  
 
General Discussion 
 
Animals were familiarized with handling before the treatment began. Even so, 
future studies could give a long period of recovery after implantation of the catheter and 
brain cannulas. This could further reduce anxiety associated with handling and blood 
draws. Bloods draws were done in the least anxiety-inducing manner, to prevent 
confounding of the data. Changes in blood glucose levels were adequate in the animals 
included in the study. A portion of the rats could not be included due to their lack of 
hypoglycemia on the days leading up to the final day and tissue euthanasian. Rats 
included typically had experimental blood glucoses levels below 60mg/dl, and showed 
physical signs of hypoglycemia. Blood glucose testing was done either during the 
administration of insulin and saline, or after the experimental period using a glucose 
analyzer. This should not give skewed results. Another limitation includes the small 
sample size. A clear statistical trend was noted, despite the low number of rats. Future 
studies will include increased sample size to meet the initial desired numbers. 
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One additional change to be made would be to take a plasma sample on the day of 
the ODN injection. This would give an idea if elevated catecholamine levels were 
detected in the antisense rats verses the control rats. Time would need to be taken after 
injections, as the handling of the rats would cause a large spike in stress hormones. It 
would need to be prompt enough so that the level would not have decreased, if a change 
did occur due to the injection of the ODN and the limited available lactate into the 
neuronal cells. Insulin could possibly be administered to the rats on day 1, soon after the 
ODN injections, with the only limiting factor being the rate at which the protein is turned 
over and a notable decrease in expression is present.  
 Western blotting of the VMH tissues showed that the ODN for MCT2 knockdown 
was effective. For the majority of rats, the expression of MCT2 was reduced by about 
50%, while the non-respondent group showed much higher levels of knockdown. The 
ODNs exceeded our presumed level of effectiveness. This could be due to the larger 
injected amount compared to other studies that have used the same ODN for knockdown. 
The western blotting of MCT1 showed that for the majority the ODN for MCT2 did not 
have a deleterious effect on its expression, as expect. The western blotting for rats who 
were non-respondents showed a statistical knockdown in MCT1 level. This could 
indicate that high concentrations of ODN have a disruptive effect on all proteins. Further 
research into this area should look at the effects of MCT1 and MCT4 knockdown via 
ODNs. They should be administered separately and together, as to determine the effect 
on the stress response and changes in the CRR. Measured changes in steady-state lactate 
could give a clue if the flow of lactate into the neuron is possibly coming into the 
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interstitial space from somewhere other than the astrocytes. Rats VMH could be taken 
and ultimately and glycogen asseys could give a better clue into the possibility of 
supercompensation. It would be impossible without tagging and imaging to determine 
where in the VMH the glycogen was forming. Tagging glucose and scanning for this 
would be the best option for following the path of the glucose after absorption. 
Preventing excess glycogen formation could prevent the development of hypoglycemic 
unawareness.  
 Further work in monocarboxylic rescue with lactate could provide some further 
depth into how MCT2 acts during knockdown. Neurons would theoretically not be able 
to take in much lactate after ODN knockdown, but this may help to overcome the effects 
of the blunted CRR in both the antisense and non-respondent groups. If rats were given a 
large dose of the different ODNs, it could be determined the threshold they knockdown 
their target protein, and at what point they being to effect other proteins. This would help 
to facilitate further studies in MCT knockdown. The use of ODNs to monitor change in 
the MCT levels could ultimately bring about a way of reducing or eliminating the 
blunting CRR to hypoglycemia. Providing a therapeutic treatment that could eliminate 
lactate availability, or glycogen utilization could prevent the lack of physiological 
awareness of the dip in glucose. This would allow the individual to consume glucose to 
bring the body back to euglycemia. This would also be useful for diabetic individuals 
who may not possess the insulin production needed to take up circulating glucose. The 
lack of initial unawareness would prevent further instances of this and allow better 
glycemic control overall
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APPENDIX A 
 
FORMULAS AND RECIPIES 
 
Mobile phase for catecholamine analysis 
Components Amount per 1L DI water 
75mm NaH2PO4 H2O (MW=137.99) 10.35g 
1.8mM 1-Octanesulfonic Acid (MW=216.3) 0.389g 
25uM Na EDTA (MW=372.24) 0.009g 
Diethylamine (DEA) 100uL 
7% Acetonitrile (ACN)  70mL 
 Tris Buffer: 45g Tris base, 5g Na EDTA in 200mL DI H2O. Bring pH to 8.6 with 
phosphoric acid. Bring total volume to 250mL and refrigerate up to 3 weeks.  
RIPA Buffer: 50mM Tris base, 1mM EDTA, 150mM NaCl, 1% NP-40, 1% 
deoxycholate, 1% SDS.  
10x TBST: 24g Tris base, 88g NaCl, 10mL Tween 20x in 1L H2O with pH adjusted to 
7.6 with phosphoric acid.  
12% Acrylamide Resolving gel: 9.9ml of DI water, 12ml Acrylamide, 7.5ml Tris 
(pH8.8), 300μl of SDS (10%), 300μl of APS, and 25μl of TEMED. 
12% Acrylamide Stacking gel: 6.8ml of DI water, 1.7ml of acrylamide, 1.25ml of Tris 
(pH 6.8), 100μl of SDS, 100μl of APS, and 15μl of TEMED. 
Electrophoresis buffer 10x: 90.8g Tris Base, 432.4g glycine and 30g SDS in 3L DI H2O. 
Transfer buffer: 90.8g Tris Base, 432.4g glycine and 20% methanol in 3L DI H2O. 
Stripping buffer: 15g Glycine, 1g SDS, 10mL Tween 20x. All in 1L DI H2O with pH 
adjusted to 2.2 with phosphoric acid.  
 
 
 
